Clinical Trials Logo

Clinical Trial Summary

This study assesses the level of distress felt by cancer patients due to the coronavirus disease 2019 (COVID-19) pandemic. Researchers also want to learn if patients prefer to receive supportive care (palliative care) in person or through telemedicine (visits by phone or video call, such as Zoom). Information from this study may help doctors better understand how COVID-19 has affected patients with advanced cancer, patients' perceptions of telehealth, and may help clinicians tailor care to patients' needs during the pandemic.

Clinical Trial Description

PRIMARY OBJECTIVES: I. Assess advanced cancer patients' level of distress due to the COVID-19 pandemic. II. Assess patients' overall preference towards palliative telemedicine vs in person visits during the COVID-19 pandemic. SECONDARY OBJECTIVES: I. Assess associations between patient characteristics and perceptions of overall distress due to the COVID-19 pandemic. II. Assess associations between patient characteristics and their attitudes and beliefs towards palliative telemedicine during the COVID-19 pandemic. III. Compare the attitudes and beliefs towards palliative telemedicine between patients who completed visits via video vs telephone. OUTLINE: Patients complete survey over 20 minutes. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05058339
Study type Observational
Source M.D. Anderson Cancer Center
Status Recruiting
Start date April 27, 2021
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04060849 - Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY Phase 1
Recruiting NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Withdrawn NCT04127721 - Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation Phase 2
Recruiting NCT03712878 - 2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies Phase 2
Recruiting NCT04314401 - National Cancer Institute "Cancer Moonshot Biobank"
Recruiting NCT04320888 - Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Phase 2
Not yet recruiting NCT05031897 - Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant Phase 2
Recruiting NCT04188912 - Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study
Recruiting NCT04592250 - Financial Toxicity in Cancer Patients
Recruiting NCT04296305 - Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain Phase 4
Recruiting NCT04060277 - Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation Phase 2
Active, not recruiting NCT02464696 - Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure N/A
Not yet recruiting NCT04874194 - Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 Phase 1/Phase 2
Recruiting NCT04820894 - Perception of Cure Among Patients With Metastatic Cancer
Active, not recruiting NCT01664910 - CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT04089358 - Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study Phase 3
Recruiting NCT04439006 - Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization Phase 2
Recruiting NCT04532372 - Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy Phase 1/Phase 2
Not yet recruiting NCT04939090 - Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients Phase 3